Chengdu Hitech Zone Becoming Gathering And Growth Highland For Biopharmaceutical Enterprises

Aerial view of Chengdu High-Tech Industrial Development Zone Frontier Medical Center. Photo: Chengdu Hi-Tech Industrial Development Zone Management Committee

Recently WestVac BioPharma Co., Ltd. Chengdu Tianfu, an international organic city in Southwest China's Sichuan province, successfully passed the patent examination and received recognition from the patent office and US trademarks, and found home-made ointments with anti-tumor properties. PMVA-1 complex for vaccination (VSK-IM02). According to reports, this project is mainly focused on treating advanced ovarian cancer and has successfully obtained patent approval in China, USA and Japan, strengthening its leading position in the world.

Chengdu Tianfu International Biocity is jointly built in Chengdu High-Tech Industrial Development Zone and Shuangliu District. Chengdu High-Tech Industrial Development Zone is an important pillar of Chengdu's biopharmaceutical industry. With the creation of large industrial clusters such as chemicals, biological agents, medical devices and modern Chinese medicine, the industrial interests are becoming more and more popular in China and the world.

In the year From the beginning of 2023, the Chengdu High-Tech Industrial Development Zone will focus on key areas such as innovative drugs and high-quality medical equipment, and has successfully attracted Fresenius Fortune Global 500 global headquarters and AG hospital projects. Southwest region. China, listed in the Fortune Global 500 list, and the country's first "Roche Digital PCR Innovation Center" to further expand the scale and level of the biopharmaceutical industry.

Chengdu Tianfu International Biocity Photo: Chengdu High-tech Industrial Development Zone Management Committee

In the year The $10 billion Luye Life Science R&D and Industrial Innovation Base Project signed by Chengdu Hi-Tech Industrial Development Zone in 2023 will invest in the construction of various sub-projects, including the Luye Life Science Comprehensive Training CDMO platform and a multi-purpose AIDS Innovation Center. The group's vice president, Gong Dequan, said Chengdu has clear geographical significance and the project will play an important role in the group's development strategy. This further expands pharmaceutical interactions and provides patients with comprehensive solutions covering the entire diagnostic, therapeutic and rehabilitation areas.

In addition, the Chengdu High-Tech Industrial Development Zone will make full use of the political leadership, mobilize the capital market and promote industrial development. In the year At the Angel Investment Summit held in China (Chengdu) in October, Angel Capital, the leading fund of Chengdu High-Tech Industrial Development Zone, signed contracts with 10 fund managers (GPS). Last year, Chengdu Hi-Tech Zone's angel fund pool size exceeded 10 billion yuan ($1.36 billion), signing contracts with 19 fund managers (GPS). The zone is also implementing a 300 billion yuan industrial development fund plan to support key industries such as electronic information, biopharmaceuticals and the digital economy.

According to data, the scale of the biopharmaceutical industry in Chengdu Hi-Tech Zone has achieved 20 percent growth for five consecutive years. It has attracted more than 150 new class 1 drug manufacturers for research and commercialization, attracting more than 100 talented local teams and a total of 10 listed and experienced companies. Today, several Fortune 500 projects are located there, such as Medtronic, AstraZeneca and GE Healthcare. The aim of the region is to become an important source of innovation for the domestic biopharmaceutical industry and an internationally influential and competitive biopharmaceutical industry cluster.

Megan collapsed in the middle of the scene.